Dyskalemia: a management problem for students.
general medicine
heart failure
hyperkalemia
hypokalemia
potassium
renal failure
students
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
17
09
2020
received:
11
06
2020
accepted:
13
10
2020
pubmed:
25
10
2020
medline:
9
10
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
Although dyskalemia is common, its management can be problematic for students and general practitioners, especially when it occurs in patients with heart and renal failure. The basic academic knowledge of general medicine students, who have often not yet encountered clinical situations of dyskalemia, remains unclear in this regard. The purpose of this study was to evaluate the knowledge and reflexive practices of general medicine students in regard to dyskalemia. A cross-sectional survey, based on a self-questionnaire, of all of the students enrolled in general medicine studies at the Faculty of Medicine at the University of Nancy (France) at the end of their degree. The students were asked questions pertaining to specific clinical situations. The answers were compared to the information provided in the medical curriculum as well as to the relevant European guidelines. We collected 290 of the questionnaires (participation rate: 81.2%). The hyper- and hypokalemia thresholds considered pathological (3.5-5.0 mmol/L) were known by 78% and 67% of the students, respectively. The perception of danger in case of severe hypokalemia was underestimated by 62.7% of them. In most cases, the proposed management of hyperkalemia in heart and renal failure did not comply with the relevant guidelines. The students tended to favor permanent discontinuation of the administration of converting enzyme inhibitors (ACE) and/or mineralocorticoid receptor antagonists (MRA) without considering the need for their reintroduction (51.6%). Sodium polystyrene sulfate was frequently seen as an appropriate first-line treatment for hyperkalemia (45%). The knowledge and competence of general medicine students appear to be lacking for hyperkalemia in heart and renal failure, and they are long way from full compliance with the relevant European guidelines. Exposure to complex clinical situations as part of the medical curriculum, therefore, seems essential to improve the way dyskalemia is managed in France.
Sections du résumé
BACKGROUND
BACKGROUND
Although dyskalemia is common, its management can be problematic for students and general practitioners, especially when it occurs in patients with heart and renal failure. The basic academic knowledge of general medicine students, who have often not yet encountered clinical situations of dyskalemia, remains unclear in this regard.
OBJECTIVES
OBJECTIVE
The purpose of this study was to evaluate the knowledge and reflexive practices of general medicine students in regard to dyskalemia.
METHODS
METHODS
A cross-sectional survey, based on a self-questionnaire, of all of the students enrolled in general medicine studies at the Faculty of Medicine at the University of Nancy (France) at the end of their degree. The students were asked questions pertaining to specific clinical situations. The answers were compared to the information provided in the medical curriculum as well as to the relevant European guidelines.
RESULTS
RESULTS
We collected 290 of the questionnaires (participation rate: 81.2%). The hyper- and hypokalemia thresholds considered pathological (3.5-5.0 mmol/L) were known by 78% and 67% of the students, respectively. The perception of danger in case of severe hypokalemia was underestimated by 62.7% of them. In most cases, the proposed management of hyperkalemia in heart and renal failure did not comply with the relevant guidelines. The students tended to favor permanent discontinuation of the administration of converting enzyme inhibitors (ACE) and/or mineralocorticoid receptor antagonists (MRA) without considering the need for their reintroduction (51.6%). Sodium polystyrene sulfate was frequently seen as an appropriate first-line treatment for hyperkalemia (45%).
CONCLUSIONS
CONCLUSIONS
The knowledge and competence of general medicine students appear to be lacking for hyperkalemia in heart and renal failure, and they are long way from full compliance with the relevant European guidelines. Exposure to complex clinical situations as part of the medical curriculum, therefore, seems essential to improve the way dyskalemia is managed in France.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-484Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Krogager M.L., Torp-Pedersen C., Mortensen R.N. et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur. Heart J. (2017) 38 104-12.
Macdonald J.E., Struthers A.D. What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol. (2004) 43 155-61.
Nilsson E., Gasparini A., Ärnlöv J. et al.Incidence and determinants of hyperkalaemia and hypokalaemia in a large healthcare system. Int. J. Cardiol. (2017) 15 277-84.
Pitt B., Bakris G., Ruilope L.M., DiCarlo L., Mukherjee R., on Behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2008) 118 1643-50.
Zannad F., McMurray J.J.V., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. (2011) 364 11-21.
Rossignol P., Zannad F., Pitt B. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. Int. J. Cardiol. (2014) 177 731-3.
Rossignol P., Dobre D., McMurray J.J.V. et al. Incidence, determinants, and prognostic significance of hyperkalaemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ. Heart Fail. (2014) 7 51-8.
Zannad F., Stough G., Rossignol P. et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur. Heart J. (2012) 33 2782-95.
Ahmed A., Zannad F., Love T.E. et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur. Heart J. (2007) 28 1334-43.
Durrieu G., Hurault C., Damase-Michel C., Montastruc J.L. Perception of risk of adverse drug reactions: a 3-year follow-up of a cohort of medical students. Fundam. Clin. Pharmacol. (2010) 24 423-7.
Bouletreau A., Chouaniere D., Wild P., Fontana J.M.Concevoir, traduire et valider un questionnaire. A propos d’un exemple, EUROQUEST. Institut National de Recherche et de Sécurité (INRS). 1999, 46 p: (accessed 2020 Jan 15th): http://www.inrs.fr/inrs/recherche/etudes-publications-communications/doc/publication.html?refINRS=B.5/2.040/3566/NS178
Collège Universitaire des Enseignants de Néphrologie, auteurs, Anomalies du bilan du potassium. Néphrologie. Réussir l'ECN 6ème édition. Paris: Ellipses; 2014. 39-50.
Ponikowski P., Voors A.A., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. (2016) 37 2129-200.
Rosano G.M.C., Tamargo J., Kjeldsen K.P., et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur. Heart J. Cardiovasc. Pharmacother. (2018) 4 180-188.
Staple B., Fleming S. Management of Hypokalaemia Clinical Guideline V2.0. Royal Cornwall Hospitals NHS Trust. August (2019). (accessed 2020 Feb 21): https://doclibrary-rcht.cornwall.nhs.uk/DocumentsLibrary/RoyalCornwallHospitalsTrust/Clinical/Pharmacy/ManagementOfHypokalaemiaClinicalGuideline.pdf
Rastergar A., Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad. Med. J. (2001) 77 759-764.
Aldahl M., Jensen A.C., Davidsen L. et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur. Heart J. (2017) 38 2890-2896.
Krogager M.L., Eggers-Kaas L., Aasbjerg K. et al. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur. Heart J. (2015) 1 245-51.
Cleland J.G., Dargie H.J., Ford I. Mortality in heart failure: clinical variables of prognostic value. Br. Heart J. (1987) 58 572-82.
Rossignol P., Girerd N., Bakris G. et al.Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur. J. Heart Fail. (2017) 19 792-799.
Schulman M., Narins R.G. Hypokalaemia and cardiovascular disease. Am. J. Cardiol. (1990) 65 4E-9E.
Cohen J.D., Neaton J.D., Prineas R.J., Daniels K.A. Diuretics, serum potassium and ventricular arrhythmias in the Multiple Risk Factor Intervention trial. Am. J. Cardiol. (1987) 60 548-54.
Salerno D.M., Asinger R.W., Elsperger J., Ruiz E., Hodges M. Frequency of hypokalaemia after successfully resuscitated out-of- hospital cardiac arrest compared with that in transmural acute myocardial infarction. Am. J. Cardiol. (1987) 59 84-8.
Johnson C.J., Peterson D.R., Smith E.K. Myocardial tissue concentrations of magnesium and potassium in men dying suddenly from ischemic heart disease. Am. J. Clin. Nutr. (1979) 32 967-70.
Kjeldsen K. Hypokalaemia and sudden cardiac death. Exp. Clin. Cardiol. (2010) 15 e96-e99.
Rossignol P., M Ruilope L., Cupisti A. et al. Recurrent hyperkalaemia management and use of renin- angiotensin-aldosterone system inhibitors. A European multi-national targeted chart review. Clin. Kidney J. (2019) 13(4) 714-719.
Mahoney B.A., Smith W.A., Lo D.S., Tsoi K., Tonelli M., Clase C.M. Emergency interventions for hyperkalaemia. Cochrane Database Syst. Rev. (2005) 2005(2) 1-66.
Elliott M.J., Ronksley P.E., Clase C.M., Ahmed S.B., Hemmelgarn B.R. Management of patients with acute hyperkalaemia. CMAJ (2010) 182 1631-1635.
Rossignol P., Legrand M., Kosiborod M. et al. Emergency management of severe hyperkalaemia: Guideline for best practice and opportunities for the future. Pharmacol. Res. (2016) 113 585-91.
Epstein M., Reaven N.L., Funk S.E., McGaughey K.J., Oestreicher N., Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am. J. Manag. Care. (2015) 21 212-220.
Beusekamp J.C., Tromp J., van der Wal H.H. et al. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur. J. Heart Fail. (2018) 20 923-930.
Ouwerkerk W., Voors A.A., Anker S.D. et al.Determinants and clinical outcome of up-titration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur. Heart J. (2017) 38 1883-1890.
Trevisan M., de Deco P., Xu H. et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur. J. Heart Fail. (2018) 20 1217-1226.
Pitt B., Zannad F., Remme W. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341 709-717.
Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348 1309-1321.
Agarwal R., Rossignol P., Romero A. et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomized, double-blind, placebo-controlled trial. Lancet. (2019) 394(10208) 1540-1550.
Pitt B., Bakris G.L., Bushinsky D.A. et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur. J. Heart Fail. (2015) 17 1057-65.
Weir M.R., Bakris G.L., Bushinsky D.A. et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N. Engl. J. Med. (2015) 372 211-21.
Anker S.D., Kosiborod M., Zannad F. et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur. J. Heart Fail. (2015) 17 1050-6.
Rafique Z., Peacock W.F., LoVecchio F., Levy P.D. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia. Expert. Opin. Pharmacother. (2015) 16 1727-34.
Viera A., Wouk N. Potassium disorders: hypokalaemia and hyperkalaemia. Am. Fam. Physician. (2015) 92 487-495.
Cohn N., Kowey P.R., Whelton P.K., Prisant L.M. New guidelines for potassium replacement in clinical practice. A contemporary review by the national council on potassium in clinical practice. Arch. Intern. Med. (2000) 160 2429-36.
Kandel O., Duhot D., Very G., Lemasson J.-F., Boisnault P. Existe-t-il une typologie des actes effectués en médecine générale ? Rev. Prat. Med. Gen. (2004) 656/657 781-84.
Gallais J.L. Actes et fonctions du médecin généraliste dans leurs dimensions médicales et sociales. Doc.Rech.Med.Gen-SFMG (1994) 1-107.
Évaluation des recours demandés par les médecins généralistes à leurs confrères des autres spécialités. Collège des généralistes enseignants du Poitou-Charentes. 1994.
Le Goaziou M.-F. L’équipement du cabinet médical. Exercer. (2003) 67 20-26.
Robin C.Etat des lieux de la pratique de l’électrocardiogramme en médecine générale en Picardie. [Thèse pour l’obtention du diplôme d’Etat de docteur en médecine]. Amiens : Université de Picardie Jules Verne Faculté de Médecine; (2018).
Lehel A.Exercice de la médecine générale avec ou sans électrocardiogramme. [Thèse pour l’obtention du diplôme d’Etat de docteur en médecine]. Bordeaux: Université de Bordeaux UFR des sciences médicales; (2015).
Kardalas E., Paschou S.A., Anagnostis P., Muscogiuri G., Siasos G., Vryonidou A. Hypokalaemia: a clinical update. Endocr. Connect. (2018) 7 135-146.
Pecoits-Filho R., Fliser D., Tu C. et al. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J. Clin. Hypertens. (Greenwich). (2019) 21 991-1001.
Drezen E., Guyet T., Happe A. From medico-administrative databases analysis to care trajectories analytics: an example with the French SNDS. Fundam. Clin. Pharmacol. (2018) 32 78.
Happe A., Drezen E. A visual approach of care pathways from the French nationwide SNDS database - from population to individual records: the ePEPS toolbox. Fundam. Clin. Pharmacol. (2018) 32 81-84.